Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials -

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Gastrointestinal disorders
Summary
One dose of rolapitant in addition to granisetron and dexamethasone, provided clinical benefit for the prevention of chemotherapy-induced nausea and vomiting for the entire 5-day at-risk period in patients receiving cisplatin-based chemotherapy (vs granisetron and dexamethasone).
UKMi comment
Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist currently in development for the prevention of chemotherapy-induced nausea and vomiting.

A related commentary discusses these study findings and the potential role of rolapitant in routine antiemetic care.
Related links: Comment